AstraZeneca Says 'IDO' To Incyte For Imfinzi Marriage

 
• By Kevin Grogan

As the major immuno-oncology players seek out the best combination therapies, AstraZeneca and Incyte are starting a Phase III trial evaluating Imfinzi and the IDO inhibitor epacadostat in Stage III NSCLC.

Wedding
Joined together: AstraZeneca and Incyte join forces with a potential lung cancer combo • Source: Shutterstock

More from Immuno-oncology

More from Anticancer